Bibliography
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128
- Dragneva G, Korpisalo P, Yla-Herttuala S. Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Dis Model Mech 2013;6(2):312-22
- Yla-Herttuala S. Cardiovascular gene therapy with vascular endothelial growth factors. Gene 2013;525(2):217-19
- Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49(10):1015-26
- Grochot-Przeczek A, Dulak J, Jozkowicz A. Therapeutic angiogenesis for revascularization in peripheral artery disease. Gene 2013;525(2):220-8
- Giacca M, Zacchigna S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther 2012;19(6):622-9
- Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107(21):2677-83
- Muona K, Makinen K, Hedman M, et al. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther 2012;19(4):392-5
- Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323(9):570-8
- Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013;15(2):65-77
- Teichler Zallen D. US gene therapy in crisis. Trends Genet 2000;16(6):272-5
- Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009;96(4):151-7
- Bryant LM, Christopher DM, Giles AR, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 2013;24(2):55-64
- Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003;42(8):1339-47
- Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007;50(11):1038-46
- Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease (ASPIRE). Available from: http://clinicaltrials.gov/ct2/show/NCT01550614 [Last accessed 20 October 2013]
- Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization (AWARE). Available from: http://clinicaltrials.gov/ct2/show/NCT00438867 [Last accessed 20 October 2013]
- EndocardialVascularEndothelialGrowth Factor D (VEGF-D) Gene Therapy for the Treatment of Severe Coronary Heart Disease (KAT301). Available from: http://clinicaltrials.gov/ct2/show/NCT01002430 [Last accessed 19 October 2013]
- Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT01757223 [Last accessed 17 October 2013]
- Kaminsky SM, Quach L, Chen S, et al. Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Hum Gene Ther Clin Dev 2013;24(1):38-46
- Gene Therapy for the Treatment of Chronic Stable Angina. Available from: http://clinicaltrials.gov/ct2/show/NCT01002495 [Last accessed 20 October 2013]
- Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. (STOP-HF). Available from: http://clinicaltrials.gov/ct2/show/NCT01643590 [Last accessed 24 October 2013]
- A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b). Available from: http://clinicaltrials.gov/ct2/show/NCT01643330 [Last accessed 18 October 2013]
- Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124(3):304-13
- AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure (AGENT-HF). Available from: http://clinicaltrials.gov/ct2/show/NCT01966887 [Last accessed 23 October 2013]
- AC6 Gene Transfer for CHF. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00787059 [Last accessed 22 October 2013]
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (VM202). Available from: http://clinicaltrials.gov/ct2/show/NCT01064440 [Last accessed 20 October 2013]
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003). Available from: http://clinicaltrials.gov/ct2/show/NCT01548378 [Last accessed 20 October 2013]
- Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia. Available from: http://clinicaltrials.gov/ct2/show/NCT01410331 [Last accessed 19 October 2013]
- Gene Therapy Clinical Trials Worldwide. Available from: http://www.abedia.com/wiley/record_detail.php?ID=292 [Last accessed 12 October 2013]
- Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD). Available from: http://clinicaltrials.gov/ct2/show/NCT00390767 [Last accessed 23 October 2013]
- Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00956332 [Last accessed 23 October 2013]
- Rutanen J, Rissanen TT, Markkanen JE, et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004;109(8):1029-35
- Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002;6(1):127-33
- Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 2009;119(6):845-56
- Ishikawa K, Aguero J, Naim C, et al. Percutaneous approaches for efficient cardiac gene delivery. J Cardiovasc Transl Res 2013;6(4):649-59
- Pacak CA, Byrne BJ. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol Ther 2011;19(9):1582-90